Page 2 - Compass Pathway News Today

For years, scientists have been looking ever more seriously at the therapeutic effect of psychedelics, which are not legal under US federal law. However, despite this renewed interest, large-scale studies…

Psychedelics show promise in treating depression: study

After 50 years of prohibition, some states are starting to challenge the federal government’s policy on psychedelic drugs.

For the nascent psychedelics sector, 2021 was the year when foundations were established for a future that may hold impressive payoffs. It remains to be seen if those payoffs will materialize in 2022,...

Compass Pathways has been aggressively using patent claims to corner the market on psychedelic-assisted treatments.

Businesses created to tackle sustainable development goals see a 127% investment increase since 2018

The biotech was priced for perfection; its data wasn't.

A bill that would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychedelics in California passed the state Senate Health Committee. The bill will now be reviewed by the Senate Appropriations Committee, after which it would move to a Senate floor vote if approved. SB 519 would decriminalize psilocybin, psilocyn, DMT, ibogaine, mescaline, LSD, ketamine and MDMA while expunging the criminal records of those convicted with low-level psyche...

Mind Medicine (OTC:MMEDF) and Mydecine Innovations Group Inc (OTC:MYCOF) often following its moves. After reaching an all-time high of $61.69 on Dec. 14, Compass Pathways consolidated for seven weeks before making another big push to the upside on Feb. 22. After failing to reach a new high on the push, it’s been in a sharp decline, plummeting 37% over the past six weeks. The sector may be in for a turnaround, however, as Compass Pathway’s stock is starting to flash bullish signals. The Com...

Alexander_Volkov/Getty Images Atai Life Sciences, the largest private psychedelics company in the world, just raised $157 million. The fresh round of capital comes months after the company closed a record $125 million in November. CEO Florian Brand told Insider the money will be used to "double down" on the companys strategy. Just months after breaking the record for largest funding round in the psychedelics field, Atai Life Sciences has raised another $157 million...